Clinical, Target, and Capital Convergence Drives Accelerated Breakthrough of China's Small Nucleic Acid Sector in 2026

　　【Pharmaceutical Network Industry DynamicsSince 2026, the market for small nucleic acid drugs in China has been developing rapidly. Pharmaceutical companies have been focusing on popular fields such as lipid-lowering, blood pressure reduction, weight loss, hepatitis B, and heart failure. Continuous advancements have been seen in clinical acceleration, target expansion, and increased capital investment.
 

Recently, Baheal Medical announced that the company plans to sign an "Investment Agreement" with SicaGene (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as "SicaGene"), agreeing to invest 27 million yuan in cash in SicaGene. After the investment, the company will hold 10% of SicaGene's equity.
 

Public information shows that SicaGene focuses on the research and development of a new generation of single-stranded oligonucleotide drugs. It has built an ASO R&D platform with complete original capabilities. Relying on this platform, multiple projects have received clinical trial application approval from China's National Medical Products Administration (NMPA). Through this collaboration, Baheal Medical will officially enter the small nucleic acid golden track, conducting multi-dimensional and in-depth cooperation with SicaGene in innovative drug R&D, manufacturing, commercialization in China and globally, as well as capital operations.
 

On March 4, CMS announced that its independently developed innovative drug INHBE small nucleic acid drug CMS-D008 injection (CMS-D008) had received the clinical trial approval notice issued by NMPA, agreeing to conduct clinical trials of CMS-D008 injection for overweight or obesity. CMS-D008 is a subcutaneous injection siRNA drug. Preclinical studies have shown that in obese animal models, the drug achieved significant weight loss and fat reduction effects without affecting muscles, with good safety, and reduced fat without losing muscle.
 

On March 2, Ribo Life Science announced that the RBD7022 injection, independently developed by the group, had completed the registration and public announcement for Phase III clinical trials by its partner Qilu Pharmaceutical, and is about to initiate Phase III clinical trials. According to the disclosure, RBD7022 injection is a siRNA drug targeting PCSK9, aimed at treating hyperlipidemia. On the same day, BeBetter Med announced that BEBT-701, a globally pioneering AGT/PCSK9 dual-target small interfering RNA (siRNA) drug independently developed by the company, had administered the first dose to a subject at the Third Xiangya Hospital of Central South University.
 

March 1 News: MWX401 Injection, independently developed by Shanghai Minwei Biotechnology, has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA), approving the product for clinical trials. MWX401 Injection is a small interfering RNA (siRNA) drug intended for the treatment of primary hypertension. According to the non-clinical study results disclosed in the announcement, MWX401 demonstrated significant blood pressure reduction and good safety in animal models.
 

In March, SYH2053 Injection, a Class 1 new drug developed by CSPC, entered Phase III clinical trials. This is an siRNA drug that achieves liver-targeted delivery through conjugation with N-acetylgalactosamine (GalNAc), targeting PCSK9 for the treatment of adult primary hypercholesterolemia or mixed dyslipidemia.
 

　　……
 

In general, since 2026, the small nucleic acid sector in China has witnessed a development boom, driven by the maturity of technology, capital investment, policy support, and industrial collaboration. In the future, influenced by multiple factors, the industry will accelerate into a golden development period characterized by innovation bursts, commercialization of chronic disease treatments, intensified global competition, and platform dominance.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.